Pancreatitis - Microbiome as Predictor of Severity II

Condition(s) studied

Study summary

The goal of this observational study is to evaluate the orointestinal microbiome and microbial derived metabolome in patients suffering from acute pancreatitis as a biomarker for severity. The main questions it aims to answer are:

* Can the orointestinal microbiome robustly predict the course of acute pancreatitis?
* How does the microbiome impact the severity of an acute pancreatitis?

Buccal/ rectal swabs, plasma and stool is collected from patients with acute pancreatitis within 48h after hospital admission.

Eligibility

Primary outcome measure(s)

• Novel microbiome species and/or functional metabolic pathways that are associated with the severity of acute pancreatitis — until discharge (up to 90 days)
  To assess the microbial diversity and differential abundances of species within buccal and rectal swabs analyzed by ONT sequencing followed by prediction of metabolic pathways and metabolites using tools such as Megan6 and GapSeq stratified by the Revised Atlanta Classification and severity (necrotic collections that require intervention and/or organ failure \>48h), adjusted for multiple individual confounders.
• Classifier developed based on differentially regulated metabolites — Until discharge (up to 90 days)
  To assess the metabolite (predicted in 1. Primary endpoint) levels in stool and plasma samples by targeted metabolomics to develop a classifier based on differentially regulated metabolites to assess its discriminatory power in predicting Revised Atlanta Classification and severity.

Trial sites (1)

More University Medical Center Goettingen trials in Germany

Other trials for the same condition